XASE
AZTR
Market cap4mUSD
Jun 12, Last price
0.29USD
1D
1.96%
1Q
-20.01%
IPO
-99.79%
Name
Azitra Inc
Chart & Performance
P/E
—
P/S
0.66
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
8m
+993.29%
Net income
-9m
L-20.53%
CFO
-10.18b
L+138,221.40%
Profile
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | ||||
Revenues | 7,500 993.29% | 686 141.55% | 284 158.18% | |
Cost of revenue | 10,992,640 | 8,728 | 10,144 | |
Unusual Expense (Income) | ||||
NOPBT | (10,985,140) | (8,042) | (9,860) | |
NOPBT Margin | ||||
Operating Taxes | (9,031) | 17 | (728) | |
Tax Rate | ||||
NOPAT | (10,976,109) | (8,059) | (9,132) | |
Net income | (8,967) -20.53% | (11,284) 5.65% | (10,680) 19.47% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 13,355 | 5,991 | 2 | |
BB yield | -830.31% | -53.83% | ||
| Debt | ||||
Debt current | 271,514 | 645 | 287 | |
Long-term debt | 285,106 | 1,450 | 8,569 | |
Deferred revenue | ||||
Other long-term liabilities | 97 | 35 | 33,765 | |
Net debt | (3,998,099) | 298 | 5,364 | |
| Cash flow | ||||
Cash from operating activities | (10,183,740) | (7,362) | (8,349) | |
CAPEX | (8,569) | (27) | (160) | |
Cash from investing activities | (379,246) | (318) | (337) | |
Cash from financing activities | 13,322 | 5,984 | 4,135 | |
FCF | (12,180,299) | (7,778) | (10,149) | |
| Balance | ||||
Cash | 4,554,719 | 1,796 | 3,493 | |
Long term investments | ||||
Excess cash | 4,554,344 | 1,762 | 3,478 | |
Stockholders' equity | (57,566) | (43,482) | (37,313) | |
Invested Capital | 6,312,025 | 47,961 | 42,546 | |
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 3,780 | 403 | 403 | |
Price | 0.43 -98.46% | 27.60 | ||
Market cap | 1,608 -85.55% | 11,130 | ||
EV | (3,996,491) | 16,543 | ||
EBITDA | (10,984,692) | (7,616) | (9,454) | |
EV/EBITDA | 0.36 | |||
Interest | 12 | 168 | 252 | |
Interest/NOPBT | ||||